Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Intangibles (Net)

Intangibles (Net) at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$38.95M-14.1%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$4.2B-10.9%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$106.17M-9.3%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$121.97M-17.2%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$534.87M-22.4%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$2.61B-25.5%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's intangibles (net)?
Supernus Pharmaceuticals (SUPN) reported intangibles (net) of $549.71M in Q1 2026.
How has Supernus Pharmaceuticals's intangibles (net) changed year-over-year?
Supernus Pharmaceuticals's intangibles (net) increased by 9.5% year-over-year, from $502.13M to $549.71M.
What is the long-term trend for Supernus Pharmaceuticals's intangibles (net)?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's intangibles (net) has grown at a 9.3% compound annual growth rate (CAGR), from $364.34M to $569.46M.
What does intangibles (net) mean?
Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.